Literature DB >> 11527136

Beta-receptor blockade, physical activity, and metabolism.

F W Lohmann1, W A Loesment, H Kaehler.   

Abstract

The adaptation processes under physical activity are regulated through an increase in the sympathetic impulse, whereby the circulation adaptation is mediated specifically by way of beta1-receptors and the energy supply predominantly by way of beta2-receptors. The maximum performance capacity, therefore, is restricted through every form of beta-blockade. However, it follows from the receptor pattern that the mixed beta1/beta2-blockade exhibits a substantially clearer effect. For everyday performance, the predominant beta1-selective blockade represents practically no handicap. The special advantages of beta1-selective-compared to nonselective-blockade are discussed. Beta1-blockers practically do not affect glycogenolysis. Under beta1/beta2-blockers, hypoglycemia could reactively lead to reflective pressure increases and bradycardia through epinephrine release. Beta1-blockers additionally influence the cellular potassium homeostasis to a substantially lower extent. Under nonselective blockers, a distinct increase in the serum potassium and a retardation of the reuptake in the cells are observed. Also, lipolysis is strongly negatively influenced under nonselective blockers. Especially for atherogenesis, the important high-density lipoprotein cholesterol is negatively influenced under nonselective blockers in contrast to selective ones. Under these aspects, results are demonstrated that were obtained in 16 hypertensive patients treated with bisoprolol. In conclusion, beta1-selective blockers are largely "metabolically neutral" and are therefore to be preferred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 11527136

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Intermittent hypoxia-induced glucose intolerance is abolished by α-adrenergic blockade or adrenal medullectomy.

Authors:  Jonathan C Jun; Mi-Kyung Shin; Ronald Devera; Qiaoling Yao; Omar Mesarwi; Shannon Bevans-Fonti; Vsevolod Y Polotsky
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-10-14       Impact factor: 4.310

2.  Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension.

Authors:  P Lijnen; R Van Hoof; A Amery
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.